PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.07%
R&D growth above 1.5x CRVO's 5.59%. Michael Burry would check for spending discipline.
-49.28%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
3.11%
Other expenses growth less than half of CRVO's 100.00%. David Dodd would verify if advantage is sustainable.
2.64%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
2.64%
Total costs growth less than half of CRVO's 15.98%. David Dodd would verify sustainability.
-60.43%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
3.11%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
0.38%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-2.64%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
70.91%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
0.38%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-60.43%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
0.38%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
3.04%
EPS growth while CRVO declines. John Neff would investigate advantages.
3.04%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
2.54%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
2.54%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.